SCHEMBL4228635

SCHEMBL4228635

[c]1cccc(OCCN2CCNCC2)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.55
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
HRH3 Q9Y5N1 3/20 0.47
HRH2 P25021 2/20 0.47
HRH1 P35367 2/20 0.47
MAPT P10636 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
SIGMAR1 Q99720 1/20 0.44
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ESR1 P03372 1/20 0.42
ESRRG P62508 2/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNA4 P43681 1/20 0.41
EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1282982 0.86 LTA4H (0.58) LTA4HKDM4EALDH1A1HRH3TDP1
SCHEMBL1418831 0.85 LTA4H (0.56) LTA4HKDM4EALDH1A1HRH3SMN1; SMN2
SCHEMBL3164063 0.84 MEN1 (0.56) LTA4HKDM4EALDH1A1HRH3SIGMAR1
SCHEMBL4231193 0.82 ALDH1A1 (0.51) LTA4HKDM4EALDH1A1LMNAMAPK1
SCHEMBL160027 0.82 NPC1 (0.56) LTA4HKDM4EALDH1A1HRH3SIGMAR1
SCHEMBL188972 0.81 LTA4H (0.60) LTA4HKDM4EALDH1A1HRH3HRH2
SCHEMBL211606 0.81 LTA4H (0.77) LTA4HKDM4EALDH1A1MAPTTDP1
SCHEMBL9122265 0.81 LTA4H (0.77) LTA4HKDM4EALDH1A1MAPTTDP1
SCHEMBL4215766 0.79 KMT2A (0.54) LTA4HKDM4EALDH1A1HRH3SIGMAR1
SCHEMBL3168401 0.79 HRH3 (0.57) KDM4EALDH1A1HRH3HRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931670-B1 PYRIDOPYRIMIDINONE INHIBITORS OF PI3K EXELIXIS INC (US) 2012-09-12 EP disclosed
US-8247408-B2 Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer EXELIXIS, INC. (US) 2012-08-21 US disclosed
US-20090062274-A1 Pyridopyrimidinone inhibitors of pi3kalpha EXELIXIS, INC (US) 2009-03-05 US disclosed
EP-1931670-A1 PYRIDOPYRIMIDINONE INHIBITORS OF PI3K Exelixis, Inc. (US) 2008-06-18 EP disclosed
WO-2007044698-A1 PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα EXELIXIS, INC. (US) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062274-A1 Pyridopyrimidinone inhibitors of pi3kalpha PIK3CA, PIK3CD, PIK3CB LTA4H 2604/4885KDM4E 2571/4885ALDH1A1 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.